Side effects, drug interactions, dosage, and pregnancy and breastfeeding safety information are provided. Reclast zoledronic acid is a prescription drug used to treat osteoporosis in men, postmenopausal women, and pagets disease. May 10, 2017 efectos secundarios del acido zoledronico. To prepare reduced doses for patients with baseline crcl less than or equal to 60 mlmin, withdraw the. Denosumab versus zoledronic acid in patients previously. Jun 06, 2016 suboptimal adherence to osteoporosis medication can reduce antifracture efficacy 4, 7 and increase health care use and costs 8, 9. It is also given every two years as an iv infusion to prevent osteoporosis. Zoledronic acid and clinical fractures and mortality after hip fracture. Reclast zoledronic acid is an injectable drug in a class of drugs referred to as bisphosphonates. Acido zoledronico zolendronato en ninos con osteogenesis. Zometa apresentacoes 4 mg100 ml via intravenosa uso adulto.
Zoledronic acid is approved for the prevention and treatment of osteoporosis in postmenopausal women. Identificacion del farmaco y autores del informe farmaco. The study reported that after receiving three years of treatment, patients who received zoledronic acid aclasta experienced. Mar 31, 2016 taiwan is currently witnessing an increasing trend in osteoporosis with age, with the mean prevalence in men and women aged 50 years or older being 1.
Effectiveness and safety of zoledronic acid in the. Zoledronic acid reclast national osteoporosis foundation. It is also approved to increase bone mass in men with osteoporosis and for the prevention of new clinical fractures in patients who have recently had a lowtrauma hip fracture. This solution is readytouse and may be administered directly to the patient without further preparation. Osteoporosis op is defined as a skeletal disorder characterized by decreased bone strength, which predisposes to an increase in fracture risk.
Efectos secundarios del acido zoledronico muy fitness. Aclasta contiene il principio attivo acido zoledronico. Oral bisphosphonates are a commonly prescribed treatment for osteoporosis, but inconvenient dosing regimens and side effects can lead to low adherence 2, 3. Acido zoledronico aclasta indicacion clinica solicitada. Denosumab or zoledronic acid in postmenopausal women with. Osteoporosis is a chronic, progressive condition that generally requires longterm management. May 20, 2015 denosumab significantly decreased srankl by 87. It is prescribed for the treatment of osteoporosis in postmenopausal women and men, pagets disease of bone in men and women, osteoporosis prevention in postmenopausal women, and the treatment of steroidinduced osteoporosis. Onceyearly zoledronic acid for treatment of postmenopausal. Effectiveness and safety of zoledronic acid in the treatment. Although more extended dosing intervals can improve adherence 2, 10, 11, efficacy remains an influential determinant of patient preference for and adherence with osteoporosis medications 12. Zometa e indicato nel trattamento dellipercalcemia neoplastica e delle fratture ossee associate a metastasi ossee.
Zoledronic acid aclasta is a potent, intravenous aminobisphosphonate administered once yearly for the treatment of osteoporosis. If you have an allergy to zoledronic acid or any other part of zoledronic acid bone health. Suboptimal adherence to osteoporosis medication can reduce antifracture efficacy 4, 7 and increase health care use and. Pdf a comparative study of use of zoledronic acid and. Menos frecuente acido zoledronico en pacientes con metastasis. In 2009, it was approved for the prevention and treatment of. Zoledronic acid increases bone density and reduces the incidence of the spine and nonspine fractures, including hip fractures. Zoledronic acid infusion for prevention and treatment of osteoporosis article pdf available in international journal of womens health 21. Aclasta 5 mg soluzione per infusioneacido zoledronico. Atencion farmaceutica en pacientes con osteoporosis. Highlights of prescribing information adequately rehydrate. To study and compare the effect of zoledronic acid and teriparatide on bone mineral density in postmenopausal women with osteoporosis. Zoledronic acid is given once a year as an intravenous iv infusion to treat osteoporosis. Black dm1, delmas pd, eastell r, reid ir, boonen s, cauley ja, cosman f, lakatos p, leung pc, man z, mautalen c, mesenbrink p, hu h, caminis j, tong k, rosariojansen t, krasnow j, hue tf, sellmeyer d, eriksen ef, cummings sr.
620 272 1094 392 704 619 948 1358 1529 719 1387 284 4 600 74 1050 1019 1459 520 131 251 1288 80 157 268 326 865 1379 1315 660 621 1203 186 963 1371 1254 556 1329 1277 26 311 951 1221 467 467 1170